Literature DB >> 10455408

Induction of apoptosis and G2/M arrest by infection with replication-deficient adenovirus at high multiplicity of infection.

K Brand1, R Klocke, A Possling, D Paul, M Strauss.   

Abstract

Replication-deficient adenoviruses are among the most widely used vectors in gene therapy and are also becoming increasingly popular as analytical tools in basic research. However, significant toxicity of these vectors in vivo has been reported. Here, we show that in an in vitro setting, first generation adenoviruses lead to growth retardation, prolongation of the G2/M phase and induction of apoptosis if applied at a high multiplicity of infection (MOI). These findings were obtained in p53-deficient hepatocytes, derived from knock-out mice (A2 cells) and in several tumor cell lines containing wild-type (wt) or mutant p53. Apoptosis induction was correlated with increased levels of p53 and bax proteins and it was stronger in cells containing wt p53 as compared with cells lacking functional p53. Apoptosis was highly dependent on the MOI used with marked effects starting at an MOI twice as high as needed for 100% gene transfer. Expression of the adenoviral E4 ORF6 gene as well as adenoviral replication were detected in all cell lines infected with first generation adenovirus. Apoptosis could be considerably reduced but not abrogated by UV inactivation of adenovirus, which indicates proapoptotic effects caused by the infection event as well as by residual adenoviral gene expression or adenoviral replication. First generation adenoviruses apparently display proapoptotic activity if used at higher MOIs, which may be of relevance when these vectors are used as analytical or gene therapeutic tools.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10455408     DOI: 10.1038/sj.gt.3300914

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  11 in total

1.  Chromosomal integration pattern of a helper-dependent minimal adenovirus vector with a selectable marker inserted into a 27.4-kilobase genomic stuffer.

Authors:  M Hillgenberg; H Tönnies; M Strauss
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

2.  Enhanced mucosal immunoglobulin A response of intranasal adenoviral vector human immunodeficiency virus vaccine and localization in the central nervous system.

Authors:  Franck Lemiale; Wing-pui Kong; Levent M Akyürek; Xu Ling; Yue Huang; Bimal K Chakrabarti; Michael Eckhaus; Gary J Nabel
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

3.  Stochastic model-assisted development of efficient low-dose viral transduction in microfluidics.

Authors:  Camilla Luni; Federica Michielin; Luisa Barzon; Vincenza Calabrò; Nicola Elvassore
Journal:  Biophys J       Date:  2013-02-19       Impact factor: 4.033

4.  Air-assisted intranasal instillation enhances adenoviral delivery to the olfactory epithelium and respiratory tract.

Authors:  P Gau; S Rodriguez; C De Leonardis; P Chen; D M Lin
Journal:  Gene Ther       Date:  2010-11-18       Impact factor: 5.250

5.  HOPX+ injury-resistant intestinal stem cells drive epithelial recovery after severe intestinal ischemia.

Authors:  Amy Stieler Stewart; Cecilia Renee Schaaf; Jennifer A Luff; John M Freund; Thomas C Becker; Sara R Tufts; James B Robertson; Liara M Gonzalez
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2021-09-22       Impact factor: 4.871

6.  Widespread phosphorylation of histone H2AX by species C adenovirus infection requires viral DNA replication.

Authors:  Gena J Nichols; Jerome Schaack; David A Ornelles
Journal:  J Virol       Date:  2009-03-25       Impact factor: 5.103

7.  Avoiding cytotoxicity of transposases by dose-controlled mRNA delivery.

Authors:  Melanie Galla; Axel Schambach; Christine S Falk; Tobias Maetzig; Johannes Kuehle; Kathrin Lange; Daniela Zychlinski; Niels Heinz; Martijn H Brugman; Gudrun Göhring; Zsuzsanna Izsvák; Zoltán Ivics; Christopher Baum
Journal:  Nucleic Acids Res       Date:  2011-05-23       Impact factor: 16.971

8.  Reversible inactivation of the transcriptional function of P53 protein by farnesylation.

Authors:  Bettina Couderc; Marie Penary; Mustapha Tohfe; Anne Pradines; Antoine Casteignau; Danièle Berg; Gilles Favre
Journal:  BMC Biotechnol       Date:  2006-05-29       Impact factor: 2.563

9.  Identification of a G(2) arrest domain in the E1 wedge E4 protein of human papillomavirus type 16.

Authors:  Clare E Davy; Deborah J Jackson; Qian Wang; Kenneth Raj; Phillip J Masterson; Nicola F Fenner; Shirley Southern; Scott Cuthill; Jonathan B A Millar; John Doorbar
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

10.  Selective intra-arterial infusion of rAd-p53 with chemotherapy for advanced oral cancer: a randomized clinical trial.

Authors:  Yi Li; Long-Jiang Li; Li-Juan Wang; Zhuang Zhang; Ning Gao; Chen-Yuan Liang; Yuan-Ding Huang; Bo Han
Journal:  BMC Med       Date:  2014-01-30       Impact factor: 8.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.